Background. Upregulation of insulin-like growth factor binding protein 2 (IGFBP-2) is often associated with aggressiveness of glioblastoma (GBM) and contributes to poor prognosis for GBM patients. In view of the regulation of b-catenin by IGFBP-2 in breast cancer and the crucial role of b-catenin pathway in glioma invasion, proliferation and maintenance of glioma stem cells, the mechanism of regulation of b-catenin by IGFBP-2, and its role in GBM prognosis was studied.
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Insulin-like growth factor binding protein-2 (IGFBP-2) is conventionally known as the modulator of IGF signaling. 2 Binding of IGFBP to IGF regulates either the bioavailability to the receptor or the half-life of IGF in circulation. 2 Upregulation of IGFBP-2 is often associated with aggressiveness of GBM and poor patient prognosis. 3 IGFBP-2 overexpression in glioma cell lines has been shown to increase migration, invasion, and chemoresistance. 4 -7 Moreover, a single chain monoclonal antibody, which we developed against IGFBP-2, inhibited invasiveness of GBM cells. 8 Although most of the IGF-independent functions of IGFBP-2 are known to occur via integrin signaling, 4, 6, 7 the underlying pathways and exact mechanisms behind their regulation remain unknown. So far in glioma, it has been shown that IGFBP-2 activates NFkB 9 and JNK 5 pathways via a5b1 integrin signaling, which is responsible for IGFBP-2-mediated survival and invasion.
Previously, we have reported the stabilization of b-catenin by IGFBP-2 in breast cancer cells and its association with lymph node metastasis. 10 However, the exact mechanism underlying this regulation and its significance with respect to GBM was unclear. The b-catenin pathway is known to play a crucial role in glioma cell proliferation, 11 invasion, 12 and maintenance of glioma-initiating cells. 13 The expression of b-catenin has been shown to increase from low-grade to high-grade glioma, 14 and its higher expression is correlated with poorer patient prognosis. 15 -17 b-catenin is known to act as a cofactor for transcription factors such as T cell factor 3 (TCF3). Embryonic stem cells, as well as poorly differentiated GBM tissues, often share a common gene signature that includes Nanog, Oct-4, and c-Myc expression, which is contributed by the activity of b-catenin-TCF complex. 18 Apart from the canonical Wnt-frizzled pathway, other known upstream regulators of b-catenin activity are EGFR 16 and integrins. 19 The RGD (arginine-glycine-aspartate) motif within the carboxy terminal domain of IGFBP-2 plays a crucial role in integrin binding and activation of integrin signaling. 6 Proteolytic cleavage of IGFBP-2 within its linker region results in N and C-terminal fragments, and these fragments are known to have reduced affinity for IGFs. 20 Considering this fact, it was assumed that IGFBP-2 loses its IGF regulatory function once cleaved. The C-terminal fragments of IGFBP-2 purified from human hemofiltrate were found to maintain their disulfide bridging pattern, 20 ability to bind to cell membrane, and induce proliferation in rat growth plate chondrocytes. 21 These studies led us to speculate that the C-terminal domain of IGFBP-2 may be sufficient to induce integrin-mediated functions of IGFBP-2. To date, a protumorigenic function of the C-terminal domain of IGFBP-2 has not been demonstrated.
In view of the above, the aim of this study was to delineate the pathway involved in IGFBP-2-mediated regulation of b-catenin and to determine if the carboxy terminal domain of IGFBP-2 has any role in b-catenin regulation and tumor growth. The current study evaluates possible cross talk between IGFBP-2-induced integrin signaling and b-catenin signaling in glioma, the 2 very important pathways involved in glioma pathogenesis.
Materials and Methods
Cell Lines, Clones, and Transfection IGFBP-2 1 -328 pcDNAmycHis, IGFBP-2 1 -204 pcDNAmycHis, IGFBP-2 205 -328 pcDNAmycHis constructs were generated by inserting PCR-amplified regions of full-length, N and C-terminal domains of IGFBP-2 in pcDNAmycHis3.1(+)A. Primer sequences are listed in Supplementary material. Table S1 . U87, LN229, U251, A172, T98G, and U373 glioma cell lines were procured in 2013 from a European collection of cell cultures (ECACC) and have been tested and authenticated by DNA profiling and karyotyping. All transfections were done using Lipofectamine 2000 (Life Technologies, USA) as per the manufacturer's protocols. U87 and LN229 stable transfectants were established by selection using G418 (Invitrogen).
Immunocytochemistry
Cells were allowed to grow on cover-slips, fixed with chilled methanol for 10 minutes, incubated with primary antibody overnight (b-catenin, #C2206, Sigma-Aldrich, 1:50), washed with PBS, and then incubated with 1:1500 dilution of anti-rabbit Alexa Flour 488 secondary antibody for 1 hour; 0.5 mg/mL of propidium iodide was used to stain nuclei.
Nuclear-cytoplasmic Fractionation, Treatments, and Western Blotting
Cytoplasmic extract was collected after lysing cells with 0.5% of Nonidet-40 (NP-40). The nuclear pellet was resuspended in lysis buffer (10 mM Tris-Cl; pH 7.4, 4 mM of EDTA, 30 mM KCl, 1% NP-40, 1 mM DTT, 100 mM of sodium ortho-vanadate, 0.5 mM PMSF, and 1x protease inhibitor cocktail from Calbiochem). For treatments, cells were incubated with 250 ng/mL of Wnt3a (R&D Systems)/20 mM of LiCl/10 mM PP2 (Calbiochem)/10 mM PP3 (Calbiochem)/10 mM RGD/10 mM focal adhesion kinase (FAK) inhibitor (Sigma-Aldrich, USA)/10 mM IGF1R (Calbiochem)/500 ng/mL of IGFBP-2 (# 674-B2, R&D Systems, USA) for 24 hours. Twenty mg of total protein was used for Western blot analysis. The antibodies used in the study were IGF1R, p-GSK3b, GSK3b, p-FAK, FAK, p-b-catenin, p-Akt (Ser 473), Akt (obtained from Cell Signaling Technologies, USA); p-Akt 1/2/3 (Thr308), IGFBP-2 (Santa Cruz, USA); b-catenin and b-Actin (Sigma-Aldrich); p-IGF1R was obtained from Abcam, UK; lamin was purchased from IMGENEX, India. IGFBP-2 (#C-18 sc6001, Santa Cruz) and b-catenin (#C2206, Sigma-Aldrich, USA) antibodies were used for immunohistochemistry. An in-house generated rabbit polyclonal anti IGFBP-2 antibody was utilized for immunohistochemistry on xenograft tissues.
Luciferase Assays
Cells were plated in 24 well dishes and after 18-24 hours were transfected with 500 ng each of IGFBP-2-pcDNAmycHis constructs + 500 ng of Top/flash reporter construct + 10 ng of Renilla luciferase construct (pRL-TK). Thirty-six hours after transfection, treatments were given for 24 hours, and cells were lysed in lysis buffer. Assays were done as per the manufacturer's protocol (Dual-Luciferase Reporter Assay System, Promega, USA).
Semiquantitative and Real-time RT-PCR
Two mg of RNA were reverse transcribed using a cDNA synthesis kit (Applied Biosystems, USA). cDNA equivalent of 20 ng of RNA was used for semiquantitative PCR. Real-time PCR reactions were performed using DyNAmoColorFlash SYBR Green qPCR Kit (Thermo Fisher Scientific India Private Ltd.) in ABI Prism 7900HT sequence detection system (Applied Biosystems, USA). The expression of RPL-35a gene and GAPDH (glyceraldehyde 3 phosphate dehydrogenase) were used as normalizing controls (Primer sequences are provided in Supplementary material. Table S2 ).
Development of Subcutaneous Xenografts in Nude Mice
Four million cells of respective clonal populations (LN229-Vc/ LN229-BP2/LN229-BP2-N/LN229-BP2-C) were injected into 4-6 week old nude mice. All animal experiments were conducted in accordance with institutional guidelines and approval of the Institutional Animal Ethics Committee. Tumor growth was Patil et al.: IGFBP-2 regulates b-catenin in GBM monitored over a period of 7 -8 weeks, after which the mice were sacrificed and tumors dissected out, weighed, and sectioned for histopathology and immunohistochemistry (IHC). IHC and characterization are described in supplementary information.
Patient Characteristics and Immunohistochemistry
Following institutional ethical committee approval and informed patient consent, tumor tissue samples of participants with newly diagnosed GBM (n ¼ 136) were obtained from patients who underwent surgery at the two clinical centers. The cohort of GBM participants received standard treatment with adjuvant radio-chemotherapy following surgery. Their survival pattern was noted over a period of 47 months. Overall survival was defined as the duration between surgery and the patient's death due to disease.
Tissue samples were formalin-fixed and paraffin-embedded. Details of the IHC staining pattern for IGFBP-2 (n ¼ 136) were retrieved from our previous study 22 and were employed for further analysis. IGFBP-2 staining was mainly cytoplasmic in the tumor cells. Similarly, 112 of 136 cases were evaluated for b-catenin based on tissue availability. In brief, the slides were deparaffinized, subjected to antigen retrieval in Tris-EDTA buffer, incubated with primary antibody (b-catenin, #C2206, Sigma-Aldrich, 1:100) followed by secondary antibody and visualized using betazoid diaminobenzidine (M1U539GL10, MACH-1 polymer detection kit). A visual semiquantitative grading scale was applied to assess the intensity of immunoreactivity for GBM tissues. The staining pattern for b-catenin was both cytoplasmic and nuclear. Only nuclear staining was considered for evaluation. The intensity was scored on a scale of zero to 2+; where zero represented nil, 1+ represented faint, and 2+ represented strong staining. Only 2+ staining was considered for analysis. The extent of staining in all cases was depicted as the labeling index (LI), which was defined as the percentage of 2+ staining tumor cells to the total number of tumor cells counted. The median LI served as a cutoff to distinguish cases with high expression from those with low (and absent) expression for IGFBP-2 and b-catenin, respectively.
Statistical Analysis
For analyzing cell line data, the nonparametric unpaired t test was utilized to calculate the P value of difference between 2 experimental datasets. All experiments with P value ≤ .05 were considered statistically significant. SPSS 15.0 statistical software (SPSS, Inc.) was used for clinical data analysis. Correlation of protein expression between IGFBP-2 and b-catenin was performed using Spearman's rho test. For correlation of protein expression with overall survival in GBMs, univariate Cox regression model was employed. Variables that were associated with P , .10 in univariate analyses were considered for inclusion into the multivariate model. Results were reported using the P values, and the estimated hazard ratio (HR). P , .05 was considered significant, and all exact 2-sided P values were reported. A median cutoff was employed to distinguish tumors with high and low expression of the proteins. Further, for clinical relevance of b-catenin and IGFBP-2, log-rank tests for significance were performed, and Kaplan-Meier curves were generated.
Results

IGFBP-2 Regulated Stabilization of Intracellular b-catenin
To establish the role of IGFBP-2-mediated protumorigenic actions in GBM, LN229 and U87 glioma cell lines stably overexpressing IGFBP-2 (U87-IGFBP-2 and LN229-IGFBP-2) were studied for b-catenin regulation. These cell lines were chosen based on their endogenous IGFBP-2 levels. 8 Western blot analysis indicated that IGFBP-2 knockdown in U251, T98G, and U373 cell lines and overexpression in LN229 and U87 cell lines resulted in concomitant decrease or increase in the intracellular b-catenin levels respectively, within 48 hours of transfection (Fig. 1A, Supplementary Material, Fig. S1A ). Also, a marked increase in intracellular b-catenin levels was observed upon overexpression of IGFBP-2 (Supplementary Material, Figs S1B and C). 
IGFBP-2-regulated Nuclear Accumulation and Activity of b-catenin Involves Inactivation of GSK3b
b-catenin is known for its rapid intracellular turnover by a destruction complex that includes axin, adenomatous polyposis coli (APC), b-catenin, and glycogen synthase kinase (GSK3b).
13
GSK3b phosphorylates b-catenin at Ser33/37/Thr41 and primes it for proteasomal degradation. 23 Phosphorylation of GSK3b at Ser9 position renders this enzyme inactive, which subsequently leads to stabilization of b-catenin. 24 IGFBP-2 knockdown in U251, T98G, and U373 cells resulted in decreased phosphorylation of GSK3b at Ser9 (Fig. 1A, Supplementary Material, Fig. S1A ). IGFBP-2 overexpression in LN229 and U87 cell lines consequently resulted in increased levels of phosphorylated GSK3b (Fig. 1A) . Therefore, inactivation of GSK3b could be one of the principal mechanisms behind IGFBP-2-mediated stabilization of b-catenin. This IGFBP-2-mediated inactivation of GSK3b resulted in concomitant decrease in the levels of phosphorylated b-catenin (Fig. 1A) . AKT is known to stabilize b-catenin by inactivating GSK3b. 25 However, only 2 cell lines out of 5 showed IGFBP-2-mediated regulation of AKT at the Thr308 position, indicating some other IGFBP-2-mediated upstream regulator of GSK3b (Fig. 1A , Supplementary Material, Fig. S1A ). Cytoplasmic stabilization of b-catenin is often found to be associated with its increased nuclear translocation and transcriptional activity. IGFBP-2 overexpression in LN229 and U87 cells resulted in increased cytoplasmic stabilization and subsequent nuclear accumulation of b-catenin that ultimately reflected in the increased b-catenin-TCF reporter activity ( Fig. 1B and C 
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GSK3b phosphorylates b-catenin at Ser33/37/Thr41 and primes it for proteasomal degradation. 23 Phosphorylation of GSK3b at Ser9 position renders this enzyme inactive, which subsequently leads to stabilization of b-catenin. 24 IGFBP-2 knockdown in U251, T98G, and U373 cells resulted in decreased phosphorylation of GSK3b at Ser9 (Fig. 1A, Supplementary Material, Fig. S1A ). IGFBP-2 overexpression in LN229 and U87 cell lines consequently resulted in increased levels of phosphorylated GSK3b (Fig. 1A) . Therefore, inactivation of GSK3b could be one of the principal mechanisms behind IGFBP-2-mediated stabilization of b-catenin. This IGFBP-2-mediated inactivation of GSK3b resulted in concomitant decrease in the levels of phosphorylated b-catenin (Fig. 1A) . AKT is known to stabilize b-catenin by inactivating GSK3b. 25 However, only 2 cell lines out of 5 showed IGFBP-2-mediated regulation of AKT at the Thr308 position, indicating some other IGFBP-2-mediated upstream regulator of GSK3b (Fig. 1A , Supplementary Material, Fig. S1A ). Cytoplasmic stabilization of b-catenin is often found to be associated with its increased nuclear translocation and transcriptional activity. IGFBP-2 overexpression in LN229 and U87 cells resulted in increased cytoplasmic stabilization and subsequent nuclear accumulation of b-catenin that ultimately reflected in the increased b-catenin-TCF reporter activity ( Fig. S2B ). In addition, there was no regulation of p-IGF1R upon IGFBP-2 overexpression, which indicated that the regulation of b-catenin by IGFBP-2 could be independent of IGF signaling (Fig. 1D ). IGFBP-2 is reported to activate FAK upon activation of integrin signaling. 21 Activation of a5b1 integrin signaling results in Src-mediated phosphorylation of FAK at Tyr925 position. 26, 27 It is reported that a5b1 integrin signaling-mediated inactivation of GSK3b acts as a survival signal for leukemic cells. 28 Moreover, integrin-activated-FAK is shown to activate HIF-1alpha via inactivation of GSK3b in GBM. 29 These earlier reports suggest that activated FAK could be the upstream 
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IGFBP-2-induced b-catenin Activity Was Integrin-signaling Dependent but IGF1R-signaling Independent
The regulation of b-catenin by IGFBP-2 may involve IGF signaling. Hence, we tested the expression of IGF-I and II upon Patil et 
regulator of GSK3b. We observed that IGFBP-2 overexpression in the LN229 or U87 cell line resulted in increased levels of p-FAK, whereas inhibition of Src-mediated activation of FAK at Tyr925 using Src antagonist PP2, abrogated IGFBP-2-mediated inactivation of GSK3b and subsequent stabilization of b-catenin ( Fig. 2A, Supplementary Material, Fig. S3A ). PP3 treatment was used as a negative control in this experiment because PP3 does not inhibit Src-mediated phosphorylation of FAK. Similar results
were obtained when these cell lines were directly treated with recombinant IGFBP-2 in the presence or absence of PP2 (Fig. 2B ) or FAK inhibitor (Supplementary Material, Fig. S3C ). This indicated that stabilization of b-catenin by IGFBP-2 involves FAK activation. On the other hand, IGFBP-2-induced inactivation of GSK3b was not inhibited upon inhibition of IGF-1 receptor signaling, which further confirmed that these effects are IGF1R-signaling independent (Fig. 2B) . One hour of treatment 
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Neuro-Oncologywith recombinant IGFBP-2 was sufficient to inactivate GSK3b, which indicated that it could be direct regulation via a series of phosphorylation events (Supplementary Material, Fig. S2C ). These results are further supported by a b-catenin-TCF responsive luciferase reporter assay. Src inhibitor PP2 and integrin inhibitor RGD peptide inhibited IGFBP-2-induced luciferase activity, while IGF1R inhibitor could not inhibit b-catenin nuclear activity (Fig. 2C ). Wnt3a and LiCl treatment or IGFBP-2 overexpression resulted in increased nuclear b-catenin activity, whereas there was no synergistic increase in the nuclear activity of b-catenin when IGFBP-2-overexpressing cells were treated with Wnt3a (Fig. 2C ). This indicated that either IGFBP-2 or Wnt3a was independently sufficient to induce the b-catenin pathway in glioma cells and might converge at a common b-catenin regulator, GSK3b. The effect of RGD and IGF1R inhibitor was confirmed by Western blot analysis for their targets p-FAK and p-IGF1R, while the activity of Wnt3a and LiCl was confirmed by analyzing expression levels of p-GSK3b (Supplementary Material, Fig. S3B ).
Carboxy Terminal Domain of IGFBP-2 Was Sufficient to Activate b-catenin Signaling
Most of the IGF binding-independent mechanisms of IGFBP-2 are attributed to the C-terminal RGD motif through which it is known to activate integrin signaling. 6 C-terminal fragments of IGFBP-2 purified from human hemofiltrate are known to have less IGF binding affinity but have an intact domain structure attributed to the disulfide bridging pattern of these fragments. 20 It was proposed that C-terminal fragments generated after proteolytic cleavage of IGFBP-2 might have a biological role in cancer progression. To investigate this, we cloned and expressed N-terminal ( 1 -165 IGFBP-2) and C-terminal domains ( 166 -289 IGFBP-2) of IGFBP-2 separately in LN229 and U87 cell lines (Supplementary Material, Fig. S4 , S5, S6A), which have low endogenous expression of IGFBP-2. Interestingly, stable overexpression of C-terminal domain of IGFBP-2 was as potent as full-length IGFBP-2 in the stabilization of b-catenin and in inducing b-catenin nuclear accumulation and activity (Fig. 3A-D) . This was also reflected in the regulation of b-catenin transcriptional targets Oct-4, Nanog, MMP2, and c-Myc in these cells (Fig. 3E, Supplementary Material,  Fig. S7D ). This C-domain-induced stabilization of b-catenin was compromised when cells were treated with PP2, which suggested that IGFBP-2 C-terminal domain alone is sufficient to induce integrin-mediated activation of b-catenin (Supplementary Material, Fig. S6B ). Moreover the C-terminal domain of IGFBP-2 induced invasion of LN229 and U87 cells (Supplementary Material, Fig. S7A-C) .
C-terminal Domain of IGFBP-2 Showed Faster in vivo Tumor Growth Than N-terminal Domain
To investigate the role of different domains of IGFBP-2 in glioma tumor progression, LN229 cells engineered to overexpress either full length IGFBP-2 (LN229-IGFBP-2/FL) or C (LN229-BP2-C) and N (LN229-BP2-N) terminal domains were subcutaneously injected into immunocompromised mice. Cells transfected with cloning vector (LN229-Vc/V) served as the control. As shown in Fig. 4 , subcutaneous xenografts developed from LN229 cells expressing full length and C-domain IGFBP-2 protein progressed faster than cells expressing N-terminal domain or vector control. The tumor sizes developed from cells expressing full length (Fig. 4A and B) or C and N terminal showed (Fig 4C -E; Supplementary  Material, Fig. S8A, S8B ) different sizes because these data were obtained from different sets of experiments.
The xenograft tissue morphology was observed by hematoxylin and eosin staining (Fig. 4F) . The immunohistochemical analysis for IGFBP-2 predominantly showed cytoplasmic staining in each subgroup with minimal nuclear staining in 2 cases. Higher IGFBP-2 expression was noted in LN229-BP2-C (C) and LN229-BP2 (FL) groups as compared with LN229-BP2-N (N) and LN229-Vc (V) groups. For b-catenin, both nuclear and cytoplasmic immunopositivity was noted in the samples. While the majority of samples from the V group showed no nuclear staining, the C and FL groups displayed considerable nuclear staining of b-catenin. Variable cytoplasmic staining was also observed in all groups. Of all the groups studied, maximum immunopositivity for both nuclear and cytoplasmic b-catenin staining and maximum cytoplasmic immunopositivity of IGFBP-2 was observed in the FL group (Fig. 4F) .
Coexpression of IGFBP-2 and b-catenin Correlated With Poorer Glioblastoma Patient Prognosis
The protein expression pattern of IGFBP-2 and b-catenin was analyzed in the tumor tissues of patients by immunohistochemistry (Fig. 5A) . Variable expression of IGFBP-2 for GBM cases (as described in our previous study) was noted, 22 with the LI (Labeling Index) ranging from zero to 70% (median LI ¼ 30%). Similarly, the nuclear expression of b-catenin was variable, with median LI being 15%. A positive correlation between IGFBP-2 and b-catenin was noted on Spearman's rho correlation (correlation coefficient ¼ 0.217, P ¼ .021).
The median age of the participants in this cohort was 47 years. The maximum follow-up period was 46 months. On univariate analysis with Cox regression models, the continuous variables such as patient age (HR: 1.022; P ¼ .014) and b-catenin expression (HR: 1.037; P ≤ .001) were noted to influence overall survival significantly. IGFBP-2 expression demonstrated a trend towards significance with respect to overall survival (HR: 1.011; P ¼ .074). Subsequently, in a multivariate Cox model, patient age (HR: 1.021; P ¼ .022) and b-catenin (HR: 1.036; P ≤ .001) were independently associated with poorer prognosis in GBM patients. However, IGFBP-2 (HR: 1.006; P ¼ .425) lost significance, indicating b-catenin to be the stronger indicator of poor prognosis than IGFBP-2 expression.
For the purpose of clinical utility, all cases were dichotomized as high (n ¼ 78) and low (n ¼ 58) expression of IGFBP-2 based on the median LI cutoff of 30% (Supplementary material, Table S3 ). On Kaplan-Meier survival analysis, the prognostic association of IGFBP-2 trended towards significance (P ¼ .071; Fig. 5B ) with a median survival of 13 months in patients with high expression of IGFBP-2 versus 18 months for those with low expression. Similarly, with a median LI cutoff of 15% for nuclear b-catenin, patients with high expression of b-catenin (n ¼ 57) had a significantly worse prognosis with a median survival of 12 months versus 19 months in patients with low expression of b-catenin (n ¼ 55) (P ¼ .002; Fig. 5C ).
Further, we evaluated the effect of coexpression of b-catenin and IGFBP-2 and noted that a combinatorial high
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IGFBP-2-induced b-catenin Activity Was Integrin-signaling Dependent but IGF1R-signaling Independent
Discussion
Despite recent advances in the treatment of GBM, the median survival has been in the range of 13 -17 months. Our previous study, 22 which corroborated other reports, 3, 6 suggested overexpression of IGFBP-2 in GBM. However, the role of IGFBP-2 in the pathogenesis of GBM is not clear. Here we demonstrate, for the first time, IGFBP-2 as the upstream regulator of b-catenin signaling in glioma. We observed that IGFBP-2 regulates stabilization and nuclear activity of b-catenin, which was in agreement with our earlier study in breast cancer. 10 However, in contrast to our observation in breast cancer, regulation of b-catenin was independent of IGF1R signaling in glioma. One probable reason for this could be that IGFBP-2 did not regulate IGFs in glioma 
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IGFBP-2-induced b-catenin
Although our emphasis is upon the IGFBP-2-induced nuclear activity of b-catenin, we also observed a marked accumulation of b-catenin in the cytoplasm upon overexpression of IGFBP-2 Fig. S1C ). There are reports that discuss the role of cytoplasmic b-catenin in stabilizing oncogenic mRNAs such as Cox2, 31 IL6, CA9, and SNAIL2. 32 In concordance with this, the protumorigenic role of these molecules has been demonstrated in GBM. 33 -36 One more novel finding of this study is the demonstration of biological activity of the C-terminal fragments of IGFBP-2 in glioma tumorigenesis. It has been proposed that IGFBP-2 fragments might have important biological function. 21 In the background of upregulated IGFBP-2 and increased protease activity in GBM tissues, it is important to study if any such mechanism exists in vivo. Interestingly, C-terminal domain of IGFBP-2, which contains the RGD motif, was sufficient to activate b-catenin signaling and also showed faster in vivo tumor growth. This suggests that C-terminal domain of IGFBP-2 has the protumorigenic role and is probably the mediator of IGFBP-2 associated GBM aggressiveness. This study advocates that under physiological circumstances, cleaved C-terminal fragment of IGFBP-2 might play an important role in the invasiveness of GBM in an IGF-independent manner since IGFBP-2 is known to lose its IGF binding affinity once cleaved. These in vitro and in vivo experiments for the first time elucidate a mechanism of IGFBP-2-induced b-catenin signaling and demonstrate a protumorigenic role for IGFBP-2 C-terminal fragment.
As mentioned before, there was a weak correlation between IGFBP-2 and b-catenin staining on GBM tissues when the Spearman rank correlation coefficient was considered. One probable reason behind this discordance could be the fact that b-catenin stabilization and activity are regulated by multiple upstream regulators such Wnt-frizzled signaling and EGFR 16 signaling. Activation of these pathways along with IGFBP-2-integrin activation could be playing an important role in the subsequent regulation of b-catenin signaling. Further, tissues showing the high coexpression of IGFBP-2 and b-catenin had the worst patient prognosis, suggesting that IGFBP-2-integrin interaction might be responsible for activation of multiple arms of signaling such as NFkB 9 and JNK 5 besides b-catenin signaling, which ultimately determines aggressiveness of tumor and the poorer prognosis of patients.
In conclusion, this study establishes IGFBP-2 as the upstream regulator of the b-catenin pathway in GBM and demonstrates the mechanism behind this regulation (Fig. 6) . We observed that IGFBP-2 or its C-terminal domain bind to the cell surface integrins and activate FAK. Activation of FAK in turn leads to the phosphorylation and inactivation of GSK3b. Inactivation of GSK3b results in the stabilization and increased nuclear activity of b-catenin. This IGFBP-2-induced b-catenin activity could be a major contributor in determining IGFBP-2-mediated aggressiveness of GBM. Ability of C-terminal domain of IGFBP-2 to activate b-catenin signaling and tumor growth in vivo makes it an attractive target for therapeutic intervention.
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GSK3b phosphorylates b-catenin at Ser33/37/Thr41 and primes it for proteasomal degradation. 23 Phosphorylation of GSK3b at Ser9 position renders this enzyme inactive, which subsequently leads to stabilization of b-catenin. 24 IGFBP-2 knockdown in U251, T98G, and U373 cells resulted in decreased phosphorylation of GSK3b at Ser9 (Fig. 1A, Supplementary Material, Fig. S1A ). IGFBP-2 overexpression in LN229 and U87 cell lines consequently resulted in increased levels of phosphorylated GSK3b (Fig. 1A) . Therefore, inactivation of GSK3b could be one of the principal mechanisms behind IGFBP-2-mediated stabilization of b-catenin. This IGFBP-2-mediated inactivation of GSK3b resulted in concomitant decrease in the levels of phosphorylated b-catenin (Fig. 1A) . AKT is known to stabilize b-catenin by inactivating GSK3b. 25 However, only 2 cell lines out of 5 showed IGFBP-2-mediated regulation of AKT at the Thr308 position, indicating some other IGFBP-2-mediated upstream regulator of GSK3b (Fig. 1A , Supplementary Material, Fig. S1A ). Cytoplasmic stabilization of b-catenin is often found to be associated with its increased nuclear translocation and transcriptional activity. IGFBP-2 overexpression in LN229 and U87 cells resulted in increased cytoplasmic stabilization and subsequent nuclear accumulation of b-catenin that ultimately reflected in the increased b-catenin-TCF reporter activity (Fig. 1B and C) . 
IGFBP-2-induced b-catenin
